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Abstract
Background Renal ischemia–reperfusion predisposes to
acute kidney injury (AKI) and mortality. APAC, mast cell
heparin proteoglycan mimetic is a potent dual antiplatelet
and anticoagulant inhibiting thrombosis in several vascular
models.
Methods Clinically relevant (0.06 and 0.13 mg/kg) and
high (0.32 and 7.3 mg/kg) heparin doses of APAC and
unfractionated heparin (UFH) were administered i.v. in
pharmacological studies. Antithrombotic action of APAC
and UFH was assessed with platelet aggregation to colla-
gen, activated partial thromboplastin (APTT) and pro-
thrombin (PT) times. Pharmacodynamics of [64Cu]-APAC
or -UFH were monitored by PET/CT. Next, APAC and
UFH doses (0.06 and 0.13 mg/kg) were i.v. administered
10 min prior to renal ischemia–reperfusion injury (IRI) in
rats.
Results APAC in contrast to UFH inhibited platelet
aggregation. During 0.06 and 0.13 mg/kg dose regimens
APTT and PT remained at baseline, but at the high APTT
prolonged fourfold to sixfold. Overall bio-distribution and
clearance of APAC and UFH were similar. After bilateral
30-min renal artery clamping, creatinine, urea nitrogen and
neutrophil gelatinase-associated lipocalin concentrations
and histopathology indicated faster renal recovery by
APAC (0.13 mg/kg). APAC, unlike UFH, prevented
expression of innate immune ligand hyaluronan and tubu-
lointerstitial injury marker Kim-1. Moreover, in severe
bilateral 1-h renal artery clamping, APAC (0.13 mg/kg)
prevented AKI, as demonstrated both by biomarkers and
survival. Compatible with kidney protection APAC
reduced the circulating levels of vascular destabilizing and
pro-inflammatory angiopoietin-2 and syndecan-1. No tissue
bleeding ensued.
Conclusion APAC and UFH were similarly eliminated via
kidneys and liver. In contrast to UFH, APAC (0.13 mg/kg)
was reno-protective in moderate and even severe IRI by
attenuating vascular injury and innate immune activation.
Keywords Ischemia–reperfusion injury  Acute kidney
injury  Unfractionated heparin  APAC
Introduction
Ischemia–reperfusion injury (IRI) of the kidney is the
major clinical problem after aortic surgery, renal artery
revascularization, and transplantation. Renal IRI is
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associated with high morbidity and mortality rates and
creates an economic burden due to prolonged hospitaliza-
tion and potential need for hemodialysis [1, 2]. IRI is
characterized by a series of rapid glomerular and tubular
damages. These predispose to deleterious short- and long-
term consequences, such as acute kidney injury (AKI), and
delayed function and increased immunogenicity of the
allograft [3, 4].
Microvascular endothelial dysfunction is pivotal in
kidney IRI [5]. Endothelial cell activation and barrier dis-
ruption by hypoxia and loss of vascular wall integrity
predispose to thrombosis, enhanced permeability, and
leukocyte adhesion [6–8]. Moreover, an extracellular
matrix protein hyaluronic acid (HA) is abundant after
kidney IRI [9, 10], its low molecular weight fragments
acting as an endogenous danger ligand for innate immunity
[11]. In experimental kidney IRI models, targeting
microvascular integrity and innate immunity appears pro-
tective [12, 13]. In clinical practice, however, the feasible
strategies to limit early IRI and subsequent immunological
and tissue remodeling responses remain scarce.
Anticoagulation by unfractionated heparin (UFH) is
commonly administered during vascular procedures. A few
studies have reported that UFH exerts limited capacity to
reduce kidney IRI [14–17]. In these studies, the protective
heparin effects were antithrombin mediated, however,
heparin carries also anticoagulation-independent anti-in-
flammatory properties: inhibition of endothelial selectins,
neutrophil infiltration, and complement activation. Intra-
operative use of UFH has failed to protect from thrombosis
in cadaveric renal allografts [18–20]. However, preopera-
tively initiated treatment with modified hyper-sulfated non-
anticoagulant heparins reduced inflammation and chronic
allograft nephropathy in experimental models of kidney
IRI and allogeneic transplantation [21]. Interestingly, a
multi-arm heparin conjugate coating protected hypoxic
endothelial cells in vitro. These conjugates localized in the
inner vessel surface in kidneys from brain-dead pigs, and
reduced blood cell interactions in a vascular wound model
in vivo [22, 23].
Semisynthetic antiplatelet and anticoagulants (APACs)
are heparin proteoglycan mimics with dual antiplatelet and
anticoagulant action [24, 25]. Briefly, APAC represents
mast cell-derived heparin proteoglycans in the form of a
semisynthetic conjugate of UFH and a protein core. In
extensive in vitro and in vivo studies, we have shown that
APAC is a unique locally acting antithrombotic. It
specifically inhibits collagen-induced platelet aggregation,
platelet deposition on injured arteries and additionally
reduces fibrin formation, being an anticoagulant. In two
baboon arterial thrombosis models, locally administered
APAC inhibited platelet deposition to vascular injury sites
or collagen surface, reduced formation or growth of
thrombus and of fibrin in situ on the collagen-coated shunt
[25]. Here, we studied the pharmacokinetic and pharma-
codynamic profiles of APAC and UFH using labeling
techniques and coagulation times, respectively. Subse-
quently, we examined for the first time whether intravenous
pretreatment of APAC could limit a moderate 30-min and
even severe 1-h bilateral kidney IRI.
Methods
First, we assessed the effects of dual antiplatelet and
anticoagulant (APAC) i.v. on blood cells counts. Second,
we compared APAC to UFH in platelet aggregation to
collagen and coagulation times. Third, we studied phar-
macokinetics based on coagulation times and bio-distri-
bution at clinically relevant (0.13 mg/kg) and about 60-fold
supraclinical (7.3 mg/kg) dose. Fourth, we studied APAC
in AKI using renal arterial clamping model.
Animals
For pharmacokinetics and bio-distribution, specific, patho-
gen-free, out-bred Sprague–Dawley rats (Charles River
Laboratories, USA), weighing 250–300 g (n = 4/group),
were used IPS Therapeutique Inc., Sherbrooke, Canada. For
kidney IRI male Sprague–Dawley rats (Harlan Laborato-
ries; Horst, Nederland) weighing 250–300 g (n = 8/group)
were subjected to bilateral renal artery clamping. Regular
rat food and tap water ad libidum were given and the rats
were maintained on a 12-h light/dark cycle.
Activated partial thromboplastin time and blood cell
counts
To assess activated partial thromboplastin time (APTT),
rats were administered (i.v, penile vein) either with APAC
(APAC2; Aplagon Oy, Helsinki, Finland) or UFH (Leo
Pharma, Ballerup, Denmark) at equivalent heparin doses of
0.06, 0.13 or 0.32 mg/kg (n = 5–8 rats/group). At 10 min
after sample administration, blood was drawn by cardiac
puncture in 3.8 % sodium citrate and rats were euthanized.
To collect platelet-poor plasma (PPP) blood was cen-
trifuged at 1200g for 15 min, and re-centrifuged at
16,100g for 5 min. APTT (Dade Actin FSL reagent, cat
no B4219-1, CaCl2, cat no ORHO37, Siemens, Munich,
Germany) was measured with Sigma Amelung KC4 Delta
coagulometer (Sigma Amelung, Lemgo, Germany) for the
maximal recording time of 180 s. Next, we studied the
effects of APAC on blood cell counts. Rats were admin-
istered (i.v. penile vein) with APAC. Blood cell counts
were determined with Sysmex KX-21 (Sysmex Corpora-
tion, Kobe, Japan).
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Collagen-induced platelet aggregation
APAC and UFH (3 lg/ml; compatible with systemic heparin
dosing of approximately 0.20 mg/kg) were studied in vitro in
collagen-induced platelet aggregation (Chrono-par colla-
gen, cat no 385, at 2 lg/ml, Chrono-log aggregometer,
Chrono-log Corp., Havertown, PA) using platelet-rich
plasma (PRP). From an anesthetized rat, blood (5–7 ml) was
collected in 3.2 % sodium citrate by cardiac puncture and
centrifuged at 200g, 10 min to obtain PRP (3.5 9 108 pla-
telets/ml) for aggregation studies. Residual blood was cen-
trifuged at 2000g, 10 min for PPP for aggregation settings.
Pharmacokinetics analysis with APTT and PT
Rats were injected with APAC and UFH at 0.13 and
7.3 mg/kg in the tail vein (n = 4/group). Blood clearance
rate from the serial jugular or the contra-lateral tail vein
sampling (3.2 % sodium citrate) was determined at 5, 60,
and 90 min, and at 6, 24, and 48 h. APTT was evaluated
with Actin FSL (cat no B4219-1; CaCl2, cat no ORHO37,
Siemens, Munich, Germany) and PT using Thromborel S
reagents (cat no OUHP29-PK, Siemens) up to 120 s.
Bio-distribution analysis
Male rats were injected with [64Cu]—labeled 1,4,7-triaza-
cyclononane-1,4,7-triacetic acid (NOTA)-APAC
(n = 4/group) and NOTA-UFH (n = 3/group) at 0.13,
0.50, and 7.3 mg/kg in the tail vein. The distribution in
kidneys, lungs, spleen, liver, and heart was followed over
48 h by static imaging using LabPET-8 PET/CT scanner at
1.2 mm resolution (n = 2/group). Rats were euthanized at
48 h and the radioactivity in blood, kidneys, lungs, spleen,
liver, heart, and muscles was measured by Cobra Gamma
Counter (GMI, Inc. Ramsey, MN, USA). Data were cor-
rected for background radioactivity and decay of 64Cu
(half-life of 12.7 h), and the radioactivity concentration
was expressed by injected dose (ID) normalized by weight
of the tissue (% ID/g).
Renal artery clamping model
The rats (n = 8/group) in a blinded set-up received 0.06,
0.13 or 0.32 mg/kg of APAC or UFH in penile vein (i.v.) at
10 min before or after the onset of warm ischemia. Control
rats received saline vehicle i.v. The rats were anesthetized
with isoflurane (2.5 %), and a midline abdominal incision
was performed. Both renal arteries were clamped either for
30 or 60 min, depending on the study model. After clamp
removal, the kidneys were inspected for recovery of blood
flow and signs of internal bleeds, and the abdomen was
closed. The rats were administered 1 ml of saline and
0.1 ml of buprenorphine (Temgesic 0.3 mg/ml, Schering-
Plough, Kenilworth, NJ, USA) for postoperative mainte-
nance of fluid balance and pain relief, respectively.
Renal histology
Semi-quantitative assessment of histological damage of
renal cortex, excluding subcapsular area, was carried out
by senior pathologist (HH), as follows: 2-lm-thick paraf-
fin-embedded kidney samples were stained with hema-
toxylin and eosin (H&E). The severity of the parameters of
tubular injury (flattening, dilatation, casts, and necrosis)
was graded on 0–3 scale: grade 0 = no damage, grade
1 = mild, grade 2 = moderate, grade 3 = severe damage,
and the sum of the individual scores was presented as an
overall tubular injury score (0–12). The pathologist was
unaware of the treatment allocation.
ELISA
Protein measurements in serum samples were performed
with ELISA kits according to the protocols for angiopoi-
etin-2 (DANG20, Quantikine-R&D Systems, Minneapolis,
MN, USA) and syndecan-1 (SEB966Ra, designed by
Cloud-Clone Corp. Houston, TX, USA, assembled by Uscn
Life Science Inc., Cologne, Germany). Microplate reader
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used
for the analysis. Frozen (-20 C) serum samples were
thawed, briefly spun, and diluted 1:8 in 0.01 M PBS.
Standard curves were constructed by plotting the concen-
tration against mean absorbance and fitted with a second-
order polynomial equation for calculations.
Assessment of renal function and AKI
To analyze renal function and kidney injury, tail vein blood
samples were collected under anesthesia on days 1, 2, and 3
after bilateral renal artery clamping. Serum was frozen at
-20 C until further analysis of creatinine and urea nitro-
gen at the HUSLAB clinical chemistry division, Helsinki
University Hospital, Helsinki, Finland. Rat neutrophil
gelatinase-associated lipocalin (NGAL) was selected as a
biomarker for AKI. NGAL serum levels were estimated by
ELISA using mouse monoclonal anti-NGAL (ABS 039-08
from BioPorto Diagnostics A/S, Gentofte, Denmark).
Tubulointerstitial injury marker, KIM-1
For immunohistochemistry of kidney injury molecule-1
(KIM-1; AF3689 from R&D systems, Abingdon, UK),
4-lm-thick paraffin-embedded cross sections were stained
using the peroxidase ABC method (Vectastain Elite ABC
Kit, Vector Laboratories). The specimens were blocked
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for 20 min with incubation by 1.5 % normal goat serum/
PBS, pH 7.4, followed by 15 h with primary antibody
diluted (8 lg/ml) with a 0.1 % bovine serum albumin/
PBS at ?4 C. After PBS wash, endogenous peroxidase
activity was blocked by 10 min with 0.1 % hydrogen
peroxidase (30 %)/PBS. The specimens were further
incubated with biotinylated antibodies in PBS at RT for
30 min; detected with avidin–biotin horseradish complex
in the PBS at RT for 30 min, and monitored by 3-amino-
9-ethylcarbazole (AEC) substrate (Vector Laboratories).
The slides were counterstained with Mayer’s haemalum.
To determine the density of positive cells, four random
fields of each cross section quadrant were counted with
4009 magnification, and scored as a sum for a 1 mm2
surface area.
Danger-associated innate immune ligand
hyaluronan
Hyaluronan (HA) was stained from 4-lm-thick paraffin-
embedded cross sections using a specific biotinylated
bHABC hyaluronan binding complex, containing biotiny-
lated G1 domain of aggrecan and link protein, prepared
from bovine articular cartilage, detected by avidin–biotin-
peroxidase (Vector Laboratories; 1:200 dilution) with
0.05 % 3,30-diaminobenzidine (DAB) (Sigma Chemical
Co., St. Louis, MO, USA). The staining specificity was
controlled by digesting some sections with Streptomyces
hyaluronidase in the presence of protease inhibitors before
incubating the bHABP probe with hyaluronan oligosac-
charides. Ten photographs (4009 magnification) were
obtained from each sample and the positive-stained area for
hyaluronan was imaged computer-assisted (Zeiss Axion-
vision 4.4, Carl Zeiss International).
Statistics
All data are expressed as mean ± SEM and analyzed by
SPSS for Windows, version 15.0 (SPSS Inc, Chicago, IL,
USA). For two-group comparison, non-parametric Mann–
Whitney U test and parametric Student’s t test were
applied. For multiple-group comparisons, non-parametric
Kruskal–Wallis test with the Dunn post hoc test and
parametric ANOVA with Dunnett’s correction were
applied. p\ 0.05 was regarded as statistically significant.
Results
APAC has antiplatelet and anticoagulant activity
First, we assessed APTT, platelet aggregation and blood
cell counts in healthy rats treated with i.v.infusion of
APAC. APTT remained at baseline at the low doses (0.06
and 0.13 mg/kg) of APAC or UFH 10 min following
administration (Fig. 1). High dose (0.32 mg/kg) of APAC
prolonged APTT by twofold (range 16 to 40 s, p\ 0.001),
while UFH at the high dose prolonged APTT at least by
fivefold (range 72 to maximal 180 s, p\ 0.001). These
APTT assessments served for the anticoagulation moni-
toring of the relevant dosing of APAC and UFH during the
renal artery clamping.
APAC, but not UFH, inhibited collagen-induced pla-
telet aggregation in vitro at a concentration of 3 lg/ml,
compatible with 0.2 mg/kg in vivo, APAC having
maximal aggregation of 0 %; UFH 50 %; and saline
60 %.
Blood cell counts remained unchanged at 10 min after
APAC administration at doses of 0.06 and 0.13 mg/kg. At
the high dose of 0.32 mg/kg hemoglobin was transiently
reduced after APAC (p = 0.02, Online Resource
Table 1).
Similar APTT-based pharmacokinetics profiles
of APAC and UFH
In APTT-based pharmacokinetic analysis of supra-clinical
dose (7.3 mg/kg) of both APAC (range 51 to maximal
120 s) and UFH (range 25 to maximal 120 s) prolonged
APTT during 5–90 min follow-up (Fig. 2a), without any
signs of bleeding. In contrast to APTT, PT prolonged only
modestly by 1.7- to twofold during 5–60 min, but returned
to baseline at 90 min after APAC or UFH administration
(Fig. 2b). Overall, these data show that APAC and UFH
inhibited mainly the intrinsic pathway of coagulation,
















Fig. 1 Anticoagulant action of APAC and UFH. APTT (in 3.8 %
citrated plasma) 10 min after i.v. administration of APAC or UFH at
doses of 0.06, 0.13 and 0.32 mg/kg in rats. Red dashed-line represents
APTT in saline-treated rats. n = 5–8 rats/group. ***p\ 0.001
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Bio-distribution and clearance of APAC follows
heparin elimination route
[64Cu]-NOTA-APAC-based bio-distribution to kidney,
liver, spleen, lungs, blood, heart, and muscle tissues when
followed during 48 h by static imaging with PET/CT
(Fig. 2c, d). After completion of the study APAC could be
traced mainly in kidney, liver, and spleen (Fig. 2c, d). In
the UFH-treated animals mainly kidney and secondarily
liver were the sites of bio-distibution (Fig. 2c).
The exposure of [64Cu]-NOTA-APAC to blood yiel-
ded the half-life (T) 0.27 h versus UFH 0.46 h at the
dose of 0.13 mg/kg. At the dose of 0.5 mg/kg APAC T
remained at 0.24 h, whereas 7.3 mg/kg of APAC led to a
T of 0.97 h, while T was 0.38 h for UFH
(p\ 0.005). The PET scanning indicated a slower
clearance and degradation of APAC in comparison to
UFH at the ultra-high dose, whereas the APTT-adjusted
functional T of APAC was 4 h, similar to that of UFH
(Fig. 2a).
APAC decreased serum NGAL levels in a 30-min
kidney IRI model
Kidney function and tubulointerstitial injury were analyzed
after IRI. Clinically relevant dose range of APAC and UFH
was chosen: 0.06 and 0.13 mg/kg did not prolong APTT,
while APAC at an estimated 0.20 mg/kg dose inhibited
collagen-induced platelet aggregation. Furthermore, the
dose selection was based on the above pharmacokinetics
analysis and our previous animal data [25]. The rats were
randomized to either saline, UFH or APAC 10 min before
30 min clamping of both renal arteries. Serum was col-
lected daily for 3 days after reperfusion. ELISA analysis
A
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Fig. 2 Pharmacokinetics and bio-distribution of APAC and UFH by
APTT and PT and by positron emission tomography (PET). APTT
and PT-adjusted (in 3.2 % citrated plasma) half-life of a APAC and
b UFH at a supra-clinical dose of 7.3 mg/kg. To analyze bio-
distribution by PET/CT scanning until 48 h the rats were given c [64-
Cu]-NOTA labeled APAC. Bio-distribution at organ harvest at 48 h
was detected with [64-Cu]-detection by gamma counter of d APAC
and e UFH at dose of 7.3 mg/kg. No signs of bleeding were observed
in the animals. a, b n = 4, c n = 2 and d, e n = 3–4 rats/group.
*Mean radioactivity of kidney cortex and medulla
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revealed that APAC 0.13 mg/kg treatment decreased serum
NGAL levels (p\ 0.01, Fig. 3).
APAC decreased innate injury in 30-min kidney IRI
model
Right kidneys were collected 3 days after reperfusion for
histopathological analysis. The renal cortical accumulation
of innate immunity ligand, hyaluronan was reduced in
kidneys of the 0.13 mg/kg APAC-treated rats compared
with those of vehicle-treated animals (p\ 0.05, Fig. 4a).
Moreover, Kim-1 density implied decreased tubulointesti-
nal injury in kidneys of APAC-treated rats compared with
those of vehicle treatment (p\ 0.05, Fig. 4b).
Semi-quantitative analysis of tubular dilatation, epithelial





















Fig. 3 Serum levels of NGAL after 30-min bilateral kidney IRI by
APAC. To analyze the NGAL, serum was collected daily for 3 days
from APAC 0.06 and 0.13 mg/kg i.v. pretreated rats. Control rats






























































































Fig. 4 Innate immune
activation and histopathology of
kidneys following 30-min
bilateral IRI by APAC. At
3 days after reperfusion, kidney
paraffin-embedded cross
sections were stained for
a innate immunity ligand
hyaluronan, b tubulointerstitial
injury marker Kim-1 and c H&E
for histopathology in APAC
0.06 and 0.13 mg/kg i.v.
pretreated rats. a The area
positive for hyaluronan was
measured with computer-
assisted imaging. c C epithelial
casts; D tubular dilatation;
arrowhead epithelial flattening;
arrow epithelial necrosis.
Control rats received saline i.v.
IgG controls in the insets. n = 8
rats/group. *p\ 0.05
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3 days after IRI in vehicle-treated animals (Fig. 4c). Both
0.06 and 0.13 mg/kg pretreatment of APAC declined the
total tubular injury score, as only mild tubular dilatation and
flattening of epithelium were observed in isolated tubular
cross sections of APAC-treated rats (p\ 0.05 for both,
Fig. 4c). The correlation between renal cortical hyaluronan
accumulation and semi-quantitative histopathological
tubular injury score was significant (r = 0.43, p = 0.04).
Neither APAC 0.06, 0.13 nor 0.32 mg/kg had an effect
on blood cell count 3 days after administration, when
compared with the vehicle-treated control rats (Online
Resource Table 2).
UFH did not decrease innate or tubulointerstitial
injury in 30-min kidney IRI model
In contrast to APAC, tubulointerstitial injury measured for
3 days following IRI was comparable between UFH
0.13 mg/kg and vehicle-treated rats with respect to NGAL
levels (Fig. 5a). Moreover, UFH failed to protect the kid-
neys from the signals of innate immunity ligand hyaluro-
nan, tubulointestinal injury marker Kim-1, and semi-
quantitative renal injury (Fig. 5b–d).
APAC prevented endothelial angiopoietin-2
exocytosis, syndecan-1 glycocalyx shedding and AKI
in 1-h kidney IRI model
Finally, we evaluated the effects of 0.13 mg/kg APAC or
saline administered 10 min before the induction of warm
ischemia in the severe 60-min renal artery clamping model.
Rat survival was 100 % (8 of 8) in the APAC-treated, but
75 % (6 of 8) in vehicle-treated group (Fig. 6a). Vascular
activation and injury in APAC- and vehicle-treated rats
were analyzed 24 h after IRI. APAC reduced serum levels
of vascular destabilizing and pro-inflammatory angiopoi-
etin-2 (p\ 0.05, Fig. 6b) and syndecan-1 (p\ 0.01,














































































Fig. 5 Kidney function, tubulointerstitial injury, innate immune
activation, and histopathology after 30-min bilateral kidney IRI by
UFH. UFH was administered at 0.13 mg/kg i.v. 10 min before
inducing kidney IRI. To analyze kidney function and tubulointerstitial
injury serum was collected daily for 3 days to assess a NGAL.
Kidney paraffin-embedded cross sections were stained for b innate
immunity ligand hyaluronan, c tubulointerstitial injury marker Kim-1
and d H&E for histopathology. b The area positive for hyaluronan
was measured with computer-assisted imaging. d C epithelial casts;
D tubular dilatation; arrowhead epithelial flattening; arrow epithelial
necrosis. Control rats received saline i.v. n = 8 rats/group
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APAC also declined creatinine (p\ 0.05, Fig. 6d) and
urea nitrogen levels (p\ 0.05, Fig. 6e), when compared
with vehicle-treated controls.
When administering a single i.v. dose of APAC 10 min
after rather than 10 min prior to the 60-min kidney IRI, the
beneficial effects of APAC on serum creatinine and urea
nitrogen levels were lost, supporting the preventive
potential of the APAC regimen (Online Resource Fig. 1).
Discussion
In this AKI model we provided evidence that APAC, a
mast cell-derived heparin proteoglycan mimetic and a dual
antiplatelet and an anticoagulant, importantly protects the
kidneys after moderate 30 min and even severe 60 min
ischemic injury. This effect was observed with APAC but
not with the same dose of UFH. The reno-protection by
APAC infusion prior to IRI occurred under anticoagulant
conditions, assessed by APTT, which were less than
measured with UFH infusion. Moreover, the systemic
effect of APAC seemed to target the renal ischemic tissue
without any obvious signs of bleeding. Even raising the
dose to 60-fold concentration (7.3 mg/kg) did not trigger
bleeds in the pharmacokinetic studies. Comparative phar-
macokinetic analysis of APTT and PET imaging showed
heparin-like bio-distribution and elimination routes of
APAC. The local injury-associated anti-platelet properties
together with anticoagulant action in the AKI model render
APAC vasculoprotective after ischemic injury, but do not
exclude possible anti-inflammatory mechanisms.
The important role of platelets in the initial tissue repair
and vascular smooth muscle cell proliferation has been
studied in vitro, and in animal models using thrombocy-
topenic or antibodies inhibiting platelet activation [26–32].
Depending on the activation signal, both protective and
pro-inflammatory mechanisms have also been illustrated in
various animal models [33]. Three important platelet-de-
pendent mechanisms include (1) procoagulant activity and
support of thrombin generation, (2) release of platelet-
derived PF4, P-selectin, CD40 ligand, and vascular growth









































































































Fig. 6 Survival and serum biomarker levels of vascular injury,
kidney function after severe 1-h bilateral kidney IRI by APAC.
Kidneys were subjected to severe IRI in clamping both renal arteries
for 1 h, and survival (3 days), vascular injury, kidney function and rat
were analyzed. Serum was collected daily for 3 days. a Rat survival,
b, c vascular destabilizing and pro-inflammatory angiopoietin-2 and
syndecan-1 serum levels by ELISA at 24 h after IRI, and d creatinine
and e urea nitrogen in APAC 0.13 mg/kg i.v. pretreated rats. Control
rats received saline i.v. b, c Red dashed-line represents serum levels
in native rats. n = 8 rats/group. *p\ 0.05, **p\ 0.01, ***p\ 0.001
Clin Exp Nephrol (2017) 21:436–445 443
123
activation and inflammatory response to injury, and (3)
formation of neutrophil entrapment (NET), further per-
petuating inflammatory injury [34]. We have previously
provided both in vitro and in vivo evidence on APACs’
unique dual antiplatelet and anticoagulant action [25],
compatible with reduced platelet aggregation to collagen
and platelet procoagulant activity. Moreover, coagulation
is inhibited in a heparin-manner, i.e. thrombin time and
APTT are prolonged. However, compared with UFH,
APAC is more potent at decreasing thrombin-generating
capacity, especially in the presence of platelets and local
thrombosis, compatible with the attenuated platelet and
subsequent fibrin recruitment in our earlier in vivo baboon
models. We now extend these dual antiplatelet and anti-
coagulant observations to the avoidance of ischemia–
reperfusion injury, specifically to AKI. Interestingly, pre-
treatment with APAC reduced cortical accumulation of
hyaluronan, its low molecular weight fragments being
reported as a potential link between kidney IRI and innate
immune activation [9–11]. APAC—without inducing tissue
bleeds—reverses the functional and structural renal
impairments resulting from severe warm ischemia, and
maintains the overall survival of the animals. Furthermore,
the systemic anticoagulant effect with the studied doses of
APAC was less than that with UFH (Fig. 1). This suggests
that the vasculoprotective effect reaches beyond the
anticoagulation.
The adult renal microvascular network is in quiescent
state and endothelium protects from thrombogenicity and
leukocyte adhesion. In microvascular injury that occurs
during aortic surgery, renal artery revascularization, and
organ transplant, endothelial von Willebrand factor (VWF)
is exposed to mediate platelet recruitment, adhesion to
collagen, and subsequent procoagulant activation [35, 36].
In parallel, fibrin formation captures more platelets and
leukocytes. These phenomena are regulated by endothe-
lium via anticoagulant and platelet inhibitory mechanisms,
involving heparan sulphate glycosaminoglycans and
prostacyclin, nitric oxide, and ectoADPase (CD39) release
[37–39]. Upon platelet activation and release, PF4 neu-
tralizes and heparinases degrade the heparin-like mole-
cules, fostering further coagulation and platelet activation.
Additionally, the potent platelet inhibiting prostacyclin and
nitric oxide are rapidly consumed under progressing
thrombogenic and inflammatory microvascular conditions.
When vascular permeability and endothelial injury increase
the platelet contact with extracellular matrix, VWF, and
collagen promote platelet accumulation, coagulation and
enhance the existing inflammatory mechanisms [34].
Innate immune activation and histopathology analysis
after bilateral kidney IRI revealed that APAC but not UFH
was reno-protective. Moreover, our study highlights that
preoperative, but not early postoperative, administration of
APAC improves kidney function in IRI. Our earlier studies
in human blood and in several animal models illustrate that
APACs are potent inhibitors of collagen-triggered platelets
to prevent platelet deposition to both collagen and VWF
[25]. Although APAC conjugates consist of heparin and
show relatively compatible inhibition of thrombin and
intrinsic pathway of coagulation, the inhibition of platelet
aggregation and of procoagulant activity clearly distincts
APAC from traditional heparins. Collagen-induced platelet
aggregation was unaffected by UFH at clinical or supra-
clinical doses, whereas APAC dose-dependently impaired
platelet aggregation and deposition on collagen surfaces
[24, 25]. Furthermore, in baboons platelet-mediated
thrombosis under high shear rates was prevented by in situ
administered APAC, whereas in the presence of UFH those
vessels rapidly occluded. Also, in another baboon model of
collagen-coated arterio-venous shunt [25], local adminis-
tration of APAC reduced both platelet and fibrin deposi-
tion. In another perioperative study antithrombin-
dependent FXa inhibitor (fondaparinux), but not UFH,
improved recovery and reduced inflammation in severe
kidney IRI [40]. However, fondaparinux, in contrast to
heparins, is contraindicated in renal failure. In our study,
decreased endothelial glycocalyx shedding of syndecan-1
and release of permeability factor Ang-2, consolidated the
rapid vasculo-protective actions of APAC pre-treatment
against kidney IRI.
In the future randomized clinical trials should aim at
addressing whether the vasculo-protective properties of
APAC, beyond regular heparin, will limit the extent and
consequences of vascular injury.
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